See also this year's filing and all EDGAR filings for this company.
PDF Report 0001114220_2017_KERYX_BIOPHARMACEUTICALS_INC.pdf
Logs
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'PROVECTUS BIOPHARMACEUTICALS INC.', 'shared_tokens': {'biopharmaceuticals'}}, {'other_company': 'REGENERX BIOPHARMACEUTICALS INC', 'shared_tokens': {'biopharmaceuticals'}}]} |
| warning | Missing logo | subcommand.report | {} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001114220')"} |
Graph
Absolute values for 0001114220, KERYX BIOPHARMACEUTICALS INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 132,897,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 3,208,000 |
| 2 | PropertyPlantAndEquipmentNet | 4,211,000 |
| 3 | remainder_Assets | 1,111,000 |
| 4 | LiabilitiesCurrent | 21,551,000 |
| 5 | LiabilitiesNoncurrent | 1,040,000 |
| 6 | remainder_Liabilities | 127,132,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 84,553,000 |
| 9 | ResearchAndDevelopmentExpense | 29,504,000 |
| 10 | remainder_Expenses | 40,789,000 |
| 11 | remainder_Revenues | 31,983,000 |
| 12 | remainder_NetIncome | -38,252,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 141,427,000 |
| 1 | Liabilities | 149,723,000 |
| 2 | Expenses | 154,846,000 |
| 3 | Revenues | 31,983,000 |
| 4 | StockholdersEquity | -8,296,000 |
| 5 | NetIncome | -161,115,000 |
| 6 | ComprehensiveNetIncome | -161,115,000 |
| 7 | BaseVar | 258,115,500 |
| 8 | EconomicCapitalRatio | -1.20 |
Edgar->Model Mapping
Feature Distribution
